AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections

US8470834B2 · kind B2 · utility

Assignees

• Merck Sharp & Dohme LLC · US
• Southern Research Institute · US

Inventors

• Cecil D. Kwong · Decatur, US
• F. George Njoroge · Hackettstown, US
• Subramaniam Ananthan · Birmingham, US
• Feng Geng · Hamburg, DE
• Hollis S. Kezar, III · Hoover, US
• Joseph A. Maddry · Birmingham, US
• John J. Piwinski · Lebanon, US
• Robert C. Reynolds · Birmingham, US
• John A. Secrist, III · Birmingham, US
• Neng-Yang Shih · Lexington, US

Key dates

• Filing date: Aug 19, 2009
• Grant date: Jun 25, 2013
• Expiry date: Sep 11, 2029

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides compounds of Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19, and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.